Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mesoblast ( (MESO) ) has issued an update.
On February 11–12, 2026, Mesoblast reported new real-world and clinical data on its FDA-approved mesenchymal stromal cell therapy Ryoncil, presented at the 2026 Tandem Meetings of ASTCT and CIBMTR. The data showed similarly high survival in steroid-refractory acute graft-versus-host disease across children and adults, second- and third-line use, and both ruxolitinib-naive and resistant patients.
Among 53 patients treated with Ryoncil as at least third-line therapy under an Emergency IND program, 15% died before completing a full course, versus only 2% in a prior Phase 3 trial where the drug was used second-line, underscoring the benefit of earlier intervention. Mesoblast said adult EIND patients achieved day-100 survival at least comparable to pediatric patients, bolstering its plan to start a pivotal trial this quarter of early second-line Ryoncil in adults with severe steroid-refractory GVHD, aimed at securing a label extension into an adult market roughly three times larger than the pediatric segment.
The most recent analyst rating on (MESO) stock is a Hold with a $21.50 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
Mesoblast’s overall stock score reflects a company with strong growth potential but significant financial challenges. The earnings call provided positive insights into market access and product launches, which are promising for future growth. However, financial performance and valuation concerns weigh down the score, with technical indicators suggesting caution due to overbought conditions.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australia-based biotechnology company specializing in allogeneic, off-the-shelf cellular medicines targeting severe and life-threatening inflammatory conditions. Its proprietary mesenchymal lineage cell therapy platforms underpin products such as Ryoncil for steroid-refractory acute graft-versus-host disease and rexlemestrocel-L for heart failure and chronic low back pain, supported by a broad global patent estate and partnerships across major markets.
Average Trading Volume: 216,713
Technical Sentiment Signal: Buy
Current Market Cap: $2.3B
For detailed information about MESO stock, go to TipRanks’ Stock Analysis page.